FindTrial
Sign In

Cost-effectiveness analysis of bDMARDs and tsDMARDs in patients with rheumatoid arthritis

Cost-effectiveness analysis of bDMARDs and tsDMARDs in patients with rheumatoid arthritis : Conventional model simulation and alternative approaches based on real world data - Cost-effectiveness analysis of bDMARDs and tsDMARDs in patients with rheumatoid arthritis : Conventional model simulation and alternative approaches based on real world data

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000040742
Enrollment
Unknown
Registered
2020-06-22
Start date
2020-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Sponsors

Chugai Pharmaceutical Co.,Ltd. Medical Science Dept.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

MeasureTime frame
Incremental cost-effectiveness ratio (ICER) after starting treatment with each bDMARDs / tsDMARDs or MTX—

Countries

Japan

Contacts

Public ContactSatoshi Kondo

Chugai Pharmaceutical Co.,Ltd. Medical Science Dept.

kondosts@chugai-pharm.co.jp03-3273-0866

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026